CA-VELODYNE-LIDAR,-INC.
7.1.2020 03:02:12 CET | Business Wire | Press release
Velodyne Lidar, Inc. today announced Anand Gopalan as its new CEO. Gopalan, who previously was Velodyne’s CTO, assumes the position from Velodyne’s legendary founder David Hall. Hall will continue as full-time Chairman of the Board and remain actively involved in directing the company’s technology, product vision and business strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200106006044/en/
Gopalan is a distinguished engineer and technology executive with experience building and leading worldwide engineering organizations. He came to Velodyne in 2016 to form an advanced research and development team. Gopalan leads Velodyne’s customer-focused technology and product development teams to address market needs for lidar solutions designed for high performance, cost optimization and high-volume production.
Over the past three years, Gopalan has worked closely with Hall to develop the company’s technological roadmap and strategic vision. Gopalan is recognized across the industry as a thought leader in business as well as in technology. Recently, Gopalan became more active as a spokesman for the company, expertly explaining the benefits and the workings of lidar to audiences around the world. It is the policy of Velodyne to promote from within the company and Gopalan was a natural choice, having proved himself in 2019.
Gopalan and the Velodyne team look forward to building on the company’s growth trajectory. Due to the breadth and versatility of the Velodyne lidar portfolio, the company continues to make revolutionary contributions to the ever-expanding autonomous industry. Velodyne is a recognized leader in a wide range of markets including automotive, mapping, on-demand mobility, robotics, security, unmanned aerial vehicles (UAV) and more.
Under Gopalan’s leadership alongside Hall, Velodyne brought to market a series of breakthrough lidar products, including the Alpha Prime™, Velarray™, VelaDome™ and a new game-changing lidar sensor, soon to be used for powerful Advanced Driver Assistance Systems (ADAS). Due to its low cost, this sensor will advance automotive safety for the everyday car owner. At CES 2020, Velodyne will unveil the new lidar sensor and Gopalan will discuss his vision for the company at a press conference in the Velodyne booth #7520 on Tuesday, January 7, at 11:00 a.m. PST.
David Hall invented groundbreaking 3D lidar sensor technology in 2005 which set the stage for revolutionizing the automobile industry and was the foundation for Velodyne’s market leadership. The idea of leveraging lidar technology for autonomous driving came to Hall while participating in the DARPA Grand Challenge for autonomous vehicles. Holding more than 30 U.S. patents, Hall is a technology visionary and serial inventor covering a variety of applications, including lidar, audio and marine. The Intellectual Property Owners Education Foundation presented Hall with its 2018 Inventor of the Year Award.
“Anand Gopalan and I have worked side-by-side on Velodyne’s technology roadmap. He is the right executive to lead Velodyne in its next growth phase,” said Hall. “His finger is on the pulse of customer and market needs while possessing the technical brilliance and leadership skills to innovate and deliver. As Chairman, Anand has my full support while I continue to provide vision, strategize and invent.”
“David Hall is more than the founder of Velodyne, he is also the founder of our industry. I am grateful for the trust he has placed in me and excited to lead a company with such a deep history in innovation as Velodyne. We are the forefront of our market, ready to drive the age of autonomy. Velodyne is bringing improved mobility and safety through versatility, responsiveness and agility,” said Gopalan.
Elevating Gopalan to CEO will enhance the leadership team at Velodyne Lidar, running day-to-day business as the company addresses U.S. and global market opportunities. Gopalan and Hall will continue to be supported by a strong bench of Velodyne executive C-staff, including Marta Hall, Chief Marketing Officer (CMO), Rick Tewell, Chief Operating Officer (COO), Mike Jellen, Chief Commercial Officer (CCO), Drew Hamer, Chief Financial Officer (CFO), Barbara Rogan, General Counsel, and Mircea Gradu, Senior Vice President of Product and Quality.
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s Founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™ and the groundbreaking software for driver assistance, Vella™.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200106006044/en/
Contact:
Sean Dowdall Landis Communications Inc. for Velodyne Lidar, Inc. (415) 286-7121 velodyne@landispr.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom